Baby formula shelves are usually almost empty on a store in downtown Washington on May 22, 2022.
Samuel Corum | AFP | Getty Images
Abbott Nutrition resumed Saturday producing baby formula at its Sturgis, Michigan plant to address the nationwide shortage.
The company has been given the green light by the U.S. Food and Drug Administration following its “initial requirements” under its May 16 permit decree.
The company said it would restart production of EleCare, along with a formula for children struggling to digest other products, along with other specialties and metabolic formulas.
Abbott is aiming for the initial release of the EleCare product on June 20 and is working to meet the guidelines for resuming production of Similac and other formulas.
“We understand that the need for a formula is urgent and our priority is to put a high quality safe formula in the hands of families across America,” an Abbott spokesman said in a statement. “We will increase production as quickly as possible while meeting all requirements.”
Although supply problems began early in the Covid-19 pandemic, the problems worsened in part due to the closure of the Michigan plant in February as a result of a contamination study.
FDA investigations began after four children were hospitalized with bacterial infections for drinking powdered formula. Two of the children were killed.
“The FDA continues to work diligently to ensure the safe production of infant formula at Abbott Nutrition’s facilities in Sturgis, Michigan,” the FDA said in a statement.
“The agency hopes that the steps and steps being taken, and that Abbott Nutrition’s Sturgis, Michigan, facility will be able to safely resume production in the short term, means more and more baby formulas are on the way or are already on the way. said the FDA.
Abbott Nutrition is the largest manufacturer of infant formula in the US
Abbott Nutrition restarts baby formula production at reopened Michigan plant
Source link Abbott Nutrition restarts baby formula production at reopened Michigan plant